Asset
Cretostimogene Grenadenorepvec
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02365818 | phase2 | completed | 2015-06-02 | 2018-08-01 | CG Oncology, Inc. | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure |
| NCT04387461 | phase2 | completed | 2020-12-08 | 2023-03-07 | CG Oncology, Inc. | Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin |
FDA applications (0)
This company has no applications containing this asset.